Phase 4 N=189 Early Mobilization Following Mini-Open Rotator Cuff Repair
Full Thickness Rotator Cuff Tears
Primary: Change in Range of Motion (ROM)From Baseline to 24 Months — 124.4; 120.2; 73.2; 84.1 degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41 Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery
Surgery
Primary: CFU Density — 5.05; 1.55 CFU/m^3
Phase 4 N=100 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria
Anaesthesia · Cataract
Primary: Time Taken to Achieve Adequate Akinesia — 41; 41; 9; 9 participants
Phase 3 N=82 Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
Acute Coronary Syndrome · Adverse Reaction to Antiplatelet Agent
Primary: Residual Platelet Reactivity — 168; 252 PRU (P2Y12 reaction units) — p=0.006
Phase 1 N=18 Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Rectal Neoplasms
Primary: Dose Related Toxicity — 1; 0; 0; 3 event
Phase 3 N=98 Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm
Hypoxia
Primary: Episodes of Intermittent Hypoxia Per Hour — 3.6; 8.4; 3.8; 8.2 Events per hour — p=<0.05
Phase 2 N=38 Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Clostridium Difficile-associated Diarrhea
Primary: Number of Participants With Adverse Events. — 28 participants
Phase 2 N=11 TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Hepatocellular Carcinoma · Hepatocellular Cancer · Carcinoma, Hepatocellular
Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks
Phase 4 N=637 Identifying Optimal Smoking Cessation Intervention Components (Cessation)
Smoking · Smoking Cessation · Nicotine Dependence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 208; 209; 201; 216 participants — p=.341
N/A N=194 PRESTIGE Observational Study
Degenerative Cervical Disc Disease
Primary: EQ-5D — 0.59; 0.78; 0.77; 0.80 units on a scale
N/A N=67 Influence of IPV on GOR in Infants From 0 to 12 Months.
Gastro-oesophageal Reflux
Primary: Number of Refluxes — 0.48; 0.97 number of refluxes
Phase 3 N=490 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 — 36.6; 35.0; 32.5 Percentage of…
Phase 2 N=202 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 375; 393 Days — p=0.3864
N/A N=159 Safety Study of Airway Clearance Techniques in Infants.
Gastro-esophageal Reflux
Primary: Number of Refluxes — 0.48; 1.14; 1.62 number of refluxes
Phase 2 N=31 Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
Recurrent Breast Cancer · Stage IIIB Breast Cancer · Stage IV Breast Cancer
Primary: Percentage of Patients That Achieved Target Suramin Concentrations in Plasma — 88 percent of patients